PLoS One:抗血栓药有助缓解老年痴呆症

2014-02-28 佚名 生物360

近日,来自日本国立循环器官疾病研究中心的研究人员调查发现,抗血栓药物西洛他唑(Cilostazol)还具有缓解老年痴呆症的作用。他们将这一发现在线刊登在了近期的《PLOS ONE》期刊上。 西洛他唑是一种用于预防脑梗塞复发的药物,可抑制血小板聚集,扩张血管,改善脑内血流,从而预防血栓形成。老年痴呆症是脑内血管和神经细胞出现障碍,导致记忆力等认知能力下降造成的。 由于很多老年痴呆症患者都并发血管

近日,来自日本国立循环器官疾病研究中心的研究人员调查发现,抗血栓药物西洛他唑(Cilostazol)还具有缓解老年痴呆症的作用。他们将这一发现在线刊登在了近期的《PLOS ONE》期刊上。

西洛他唑是一种用于预防脑梗塞复发的药物,可抑制血小板聚集,扩张血管,改善脑内血流,从而预防血栓形成。老年痴呆症是脑内血管和神经细胞出现障碍,导致记忆力等认知能力下降造成的。

由于很多老年痴呆症患者都并发血管疾病,一些患者也会服用西洛他唑。研究人员调查了 1996 年至 2012 年间的早老性痴呆症患者病历,并且以 30 分为满分,为患者的认知功能打分。

结果发现,在能够勉强维持社会生活的患者中,只服用老年痴呆症药物的 36 名患者一年间认知功能平均下降 2.2 分,而同时服用了西洛他唑的 34 名患者则只平均下降 0.5 分。症状较轻的患者如果服用了西洛他唑,记忆和准确掌握自己所在地点的能力也出现了改善。

此前在动物实验中,研究人员曾发现西洛他唑能够促进脑内积累的废物排出。他们认为,也许是西洛他唑改善了脑内血流,使脑内积存的异常蛋白质排出到外部,从而缓解了老年痴呆症。

研究小组准备今年秋季与更多医疗机构合作,针对轻度认知障碍患者开展临床研究,以进一步确认西洛他唑对老年痴呆症的疗效。

原始出处:

Masafumi Ihara, Madoka Nishino, Akihiko Taguchi, Yumi Yamamoto, Yorito Hattori, Satoshi Saito, Yukako Takahashi, Masahiro Tsuji, Yukiko Kasahara, Yu Takata, Masahiro Okada. Cilostazol Add-On Therapy in Patients with Mild Dementia Receiving Donepezil: A Retrospective Study. PLOS ONE, 26 Feb 2014; DOI: 10.1371/journal.pone.0089516 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789574, encodeId=7f391e89574fd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 11 00:11:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994408, encodeId=b141199440892, content=<a href='/topic/show?id=4d0655e6226' target=_blank style='color:#2F92EE;'>#抗血栓药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55762, encryptionId=4d0655e6226, topicName=抗血栓药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Aug 04 09:11:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836081, encodeId=f73c183608144, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Jun 24 08:11:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574087, encodeId=36cc15e408777, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Mar 02 02:11:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789574, encodeId=7f391e89574fd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 11 00:11:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994408, encodeId=b141199440892, content=<a href='/topic/show?id=4d0655e6226' target=_blank style='color:#2F92EE;'>#抗血栓药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55762, encryptionId=4d0655e6226, topicName=抗血栓药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Aug 04 09:11:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836081, encodeId=f73c183608144, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Jun 24 08:11:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574087, encodeId=36cc15e408777, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Mar 02 02:11:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789574, encodeId=7f391e89574fd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 11 00:11:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994408, encodeId=b141199440892, content=<a href='/topic/show?id=4d0655e6226' target=_blank style='color:#2F92EE;'>#抗血栓药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55762, encryptionId=4d0655e6226, topicName=抗血栓药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Aug 04 09:11:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836081, encodeId=f73c183608144, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Jun 24 08:11:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574087, encodeId=36cc15e408777, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Mar 02 02:11:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
    2014-06-24 Boyinsh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789574, encodeId=7f391e89574fd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Dec 11 00:11:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994408, encodeId=b141199440892, content=<a href='/topic/show?id=4d0655e6226' target=_blank style='color:#2F92EE;'>#抗血栓药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55762, encryptionId=4d0655e6226, topicName=抗血栓药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Aug 04 09:11:00 CST 2014, time=2014-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836081, encodeId=f73c183608144, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Tue Jun 24 08:11:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574087, encodeId=36cc15e408777, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Sun Mar 02 02:11:00 CST 2014, time=2014-03-02, status=1, ipAttribution=)]
    2014-03-02 gwc388

相关资讯

ESC 2013:抗血栓药未充分用于预防中风

全球房颤登记研究的一年期数据揭晓- 2013年欧洲心脏病协会大会上的 GARFIELD 登记研究报告提供了有关处于风险中的房颤患者实际治疗方式的疗效数据出自创新的独立学术研究计划 GARFIELD(全球抗凝剂实地登记研究)首批研究的一年期数据结果对心房颤动(简称:房颤)患者群体中风的风险加大提供了见解。这些结果取自本周在2013年欧洲心脏病协会大会 (ESC Congress 2013) 上发